Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. It is developing first-in-class cell therapy products based on the finely tuned mechanisms for self-repair that exist in the human body. Its technology leverages and enables these mechanisms in the form of specific cells, using formulations and modes of delivery unique to each medical indication. The Company’s current product candidates include: HONEDRA® (formerly CLBS12), recipient of SAKIGAKE designation and eligible for early conditional approval in Japan for the treatment of critical limb ischemia (“CLI”) based on the results of an ongoing clinical trial; OLOGO™ (formerly CLBS14), a Regenerative Medicine Advanced Therapy (“RMAT”) designated therapy for which the Company has finalized with the U.S. Food and Drug Administration (the “FDA”) a protocol for a Phase 3 confirmatory trial in subjects with no-option refractory disabling angina (“NORDA”); CLBS16, the subject of both a recently completed positive Phase 2a study and a newly initiated Phase 2b study in the U.S. for the treatment of coronary microvascular dysfunction (“CMD”); CLBS119, an emergent CD34+ stem cell therapy responding to the COVID-19 pandemic and the potentially permanent damage the virus inflicts on the lungs of many patients; and CLBS201, designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for chronic kidney disease (“CKD”).

Company profile
Ticker
LSTA
Exchange
Website
CEO
David Mazzo
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Caladrius Biosciences, Inc., CALADRIUS BIOSCIENCES, INC., CORNICHE GROUP INC /DE, NeoStem, Inc., PHASE III MEDICAL INC/DE
SEC CIK
Corporate docs
Subsidiaries
Amorcyte, LLC • Athelos Corporation • NeoStem Oncology, LLC • As of December 31, 2019, Becton Dickinson's ownership interest in Athelos Corporation ...
IRS number
222343568
LSTA stock data
Latest filings (excl ownership)
8-K
Results of Operations and Financial Condition
6 Feb 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
8-K
Lisata Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
10 Nov 22
S-8
Registration of securities for employees
17 Oct 22
8-K/A
Financial Statements and Exhibits
14 Oct 22
8-K/A
Other Events
4 Oct 22
8-K
Other Events
29 Sep 22
424B5
Prospectus supplement for primary offering
26 Sep 22
8-K
Regulation FD Disclosure
22 Sep 22
8-K
Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics
15 Sep 22
Transcripts
LSTA
Earnings call transcript
2022 Q3
13 Nov 22
LSTA
Earnings call transcript
2022 Q2
5 Aug 22
LSTA
Earnings call transcript
2022 Q1
6 May 22
LSTA
Earnings call transcript
2021 Q4
23 Mar 22
LSTA
Earnings call transcript
2021 Q3
4 Nov 21
LSTA
Earnings call transcript
2021 Q2
6 Aug 21
LSTA
Earnings call transcript
2021 Q1
7 May 21
LSTA
Earnings call transcript
2020 Q4
26 Feb 21
LSTA
Earnings call transcript
2020 Q3
5 Nov 20
LSTA
Earnings call transcript
2020 Q2
13 Aug 20
Financial summary
Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 31.48 mm | 31.48 mm | 31.48 mm | 31.48 mm | 31.48 mm | 31.48 mm |
Cash burn (monthly) | 623.33 k | (no burn) | 12.57 mm | 4.83 mm | 1.33 mm | 1.61 mm |
Cash used (since last report) | 3.66 mm | n/a | 73.82 mm | 28.37 mm | 7.82 mm | 9.45 mm |
Cash remaining | 27.82 mm | n/a | -42.34 mm | 3.10 mm | 23.65 mm | 22.03 mm |
Runway (months of cash) | 44.6 | n/a | -3.4 | 0.6 | 17.7 | 13.7 |
Institutional ownership, Q4 2022
12.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 26 |
Opened positions | 5 |
Closed positions | 2 |
Increased positions | 7 |
Reduced positions | 6 |
13F shares | Current |
---|---|
Total value | 1.49 bn |
Total shares | 3.25 mm |
Total puts | 0.00 |
Total calls | 2.25 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
CVI Investments | 1.58 mm | $0.00 |
Intracoastal Capital | 949.61 k | $2.21 mm |
BML Capital Management | 243.84 k | $616.91 mm |
Vanguard | 176.14 k | $445.63 mm |
Renaissance Technologies | 92.12 k | $233.00 k |
Sabby Management | 68.46 k | $173.21 mm |
BLK Blackrock | 56.81 k | $143.72 mm |
Geode Capital Management | 25.97 k | $64.00 k |
Dimensional Fund Advisors | 14.95 k | $37.00 k |
STT State Street | 14.35 k | $35.73 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
13 Jan 23 | David J Mazzo | Common Stock | Payment of exercise | Dispose F | No | No | 3.65 | 397 | 1.45 k | 96,543 |
11 Jan 23 | David J Mazzo | Common Stock | Payment of exercise | Dispose F | No | No | 3.2 | 1,030 | 3.30 k | 96,940 |
10 Jan 23 | Kristen K Buck | Common Stock | Payment of exercise | Dispose F | No | No | 3.195 | 512 | 1.64 k | 35,823 |
10 Jan 23 | David J Mazzo | Common Stock | Payment of exercise | Dispose F | No | No | 3.195 | 3,470 | 11.09 k | 97,970 |
9 Jan 23 | Kristen K Buck | Common Stock | Payment of exercise | Dispose F | No | No | 3 | 2,147 | 6.44 k | 36,335 |
9 Jan 23 | Kristen K Buck | Common Stock | Grant | Acquire A | No | No | 0 | 18,000 | 0.00 | 38,482 |
9 Jan 23 | Kristen K Buck | Stock Options Common Stock | Grant | Acquire A | No | No | 3 | 9,000 | 27.00 k | 9,000 |
9 Jan 23 | David J Mazzo | Common Stock | Payment of exercise | Dispose F | No | No | 3 | 7,845 | 23.54 k | 101,440 |
9 Jan 23 | David J Mazzo | Common Stock | Grant | Acquire A | No | No | 0 | 60,000 | 0.00 | 109,285 |
9 Jan 23 | David J Mazzo | Stock Options Common Stock | Grant | Acquire A | No | No | 3 | 30,000 | 90.00 k | 30,000 |